An integrated benefit-risk assessment of cobalt-containing alloys used in medical devices: Implications for regulatory requirements in the European Union

被引:7
|
作者
Eichenbaum, Gary [1 ]
Wilsey, T. Jared [2 ]
Fessel, Gion [3 ]
Qiu, Qing-Qing [4 ]
Perkins, Laura [5 ]
Hasgall, Philippe [6 ]
Monnot, Andrew [7 ]
More, L. Sharlee [8 ]
Egnot, Natalie [9 ]
Sague, Jorge [4 ]
Marcello, Stephen [10 ]
Connor, Kevin [11 ]
Scutti, James [11 ]
Christian, V. Whitney [12 ]
Coplan, M. Paul [1 ,13 ]
Wright, John [1 ]
Hastings, Bob [1 ]
Katz, B. Laurence [14 ]
Vreeke, Mark [15 ]
Calistri-Yeh, Millie [16 ]
Faiola, Brenda [16 ,17 ]
Purushothaman, Bushan [18 ]
Nevelos, Jim [4 ]
Bashiri, Mehran [19 ]
Christensen, Jesper Bjerg [20 ]
Kovochich, Michael [21 ]
Unice, Kenneth [9 ]
机构
[1] Johnson & Johnson, 410 George St, New Brunswick, NJ 08901 USA
[2] Smith & Nephew, 1450 E Brooks Rd, Memphis, TN 38116 USA
[3] Smith & Nephew, Oberneuhofstasse 10D, CH-6340 Baar, Switzerland
[4] Stryker, 2825 Airview Blvd, Kalamazoo, MI 49002 USA
[5] Abbott Vasc, 3200 Lakeside Dr, Santa Clara, CA 95054 USA
[6] Zimmer Biomet, Sulzerallee 8, CH-8404 Winterthur, Switzerland
[7] Cardno ChemRisk, 235 Pine St,Suite 2300, San Francisco, CA 94104 USA
[8] Cardno ChemRisk, 6720 S Macadam Ave,Suite 150, Portland, OR 97219 USA
[9] Cardno ChemRisk, 20 Stanwix St,Suite 505, Pittsburgh, PA 15222 USA
[10] AJ&J Co, Ethicon, Cincinnati, OH 45242 USA
[11] Boston Sci, 100 Boston Sci Way, Marlborough, MA 01752 USA
[12] Medtron Plc, 6743 Southpoint Dr North, Jacksonville, FL 32216 USA
[13] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[14] LifeScan Global Corp, 20 Valley Stream Pkwy, Malvern, PA 19355 USA
[15] Edwards Lifesci, 1 Edwards Way, Irvine, CA 92614 USA
[16] Becton Dickinson, 1 Becton Dr, Franklin Lakes, NJ 07417 USA
[17] Rho Inc, 2635 E NC,Hwy 54, Durham, NC 27713 USA
[18] Medtron Plc, 8200 Coral Sea St NE, Mounds View, MN 55112 USA
[19] Stryker Neurovasc, 47900 Bayside Pkwy, Fremont, CA 94538 USA
[20] Novo Nordisk AS, Stenager Alle 4, DK-9800 Hjorring, Denmark
[21] Cardno ChemRisk, 30 North LaSalle St,Suite 3910, Chicago, IL 60602 USA
关键词
Weight of evidence; Benefit-risk assessment; Alternatives assessment; Carcinogenicity; Reproductive toxicity; Cobalt; Cobalt alloy; CoCrMo; Stainless steel; Medical devices; METAL-ON-METAL; TOTAL HIP ARTHROPLASTIES; REFRACTORY ANEMIA; WEAR PARTICLES; HIGH CHROMIUM; TOXICITY; BLOOD; CANCER; REPLACEMENT; IMPLANTS;
D O I
10.1016/j.yrtph.2021.105004
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
In 2017, the European Union (EU) Committee for Risk Assessment (RAC) recommended the classification of metallic cobalt (Co) as Category 1B with respect to its carcinogenic and reproductive hazard potential and Category 2 for mutagenicity but did not evaluate the relevance of these classifications for patients exposed to Co containing alloys (CoCA) used in medical devices. CoCA are inherently different materials from Co metal from a toxicological perspective and thus require a separate assessment. CoCA are biocompatible materials with a unique combination of properties including strength, durability, and a long history of safe use that make them uniquely suited for use in a wide-range of medical devices. Assessments were performed on relevant preclinical and clinical carcinogenicity and reproductive toxicity data for Co and CoCA to meet the requirements under the EU Medical Device Regulation triggered by the ECHA re-classification (adopted in October 2019 under the 14th Adaptation to Technical Progress to CLP) and to address their relevance to patient safety. The objective of this review is to present an integrated overview of these assessments, a benefit-risk assessment and an examination of potential alternative materials. The data support the conclusion that the exposure to CoCA in medical devices via clinically relevant routes does not represent a hazard for carcinogenicity or reproductive toxicity. Additionally, the risk for the adverse effects that are known to occur with elevated Co concentrations (e.g., cardiomyopathy) are very low for CoCA implant devices (infrequent reports often reflecting a unique catastrophic failure event out of millions of patients) and negligible for CoCA non-implant devices (not measurable/no case reports). In conclusion, the favorable benefit-risk profile also in relation to possible alternatives presented herein strongly support continued use of CoCA in medical devices.
引用
收藏
页数:18
相关论文
共 9 条
  • [1] Regulatory requirements and optimization of multiple criteria decision analysis to quantify the benefit-risk assessment of medical devices
    Su, Gui
    Deng, Dongyuan
    [J]. EXPERT REVIEW OF MEDICAL DEVICES, 2023, 20 (04) : 273 - 281
  • [2] Regulatory requirements for medical devices in the European Union
    Eikelboom, BC
    Duijst, P
    [J]. EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 1996, 12 (01) : 3 - 4
  • [3] Carcinogenic hazard assessment of cobalt-containing alloys in medical devices: Review of in vivo studies
    Kovochich, Michael
    Monnot, Andrew
    Kougias, Daniel G.
    More, Sharlee L.
    Wilsey, Jared T.
    Qiu, Qing-Qing
    Perkins, Laura E. L.
    Hasgall, Philippe
    Taneja, Maneesh
    Reverdy, Edward E.
    Sague, Jorge
    Marcello, Stephen
    Connor, Kevin
    Scutti, James
    Christian, Whitney V.
    Coplan, Paul
    Katz, Laurence B.
    Vreeke, Mark
    Calistri-Yeh, Millie
    Faiola, Brenda
    Unice, Kenneth
    Eichenbaum, Gary
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2021, 122
  • [4] Periodic Benefit-Risk Evaluation Report: A European Union Regulatory Perspective
    Arlett P.
    Postigo R.
    Janssen H.
    Spooner A.
    [J]. Pharmaceutical Medicine, 2014, 28 (6) : 309 - 315
  • [5] Patient-Focused Benefit-Risk Analysis to Inform Regulatory Decisions: The European Union Perspective
    Muehlbacher, Axel C.
    Juhnke, Christin
    Beyer, Andrea R.
    Garner, Sarah
    [J]. VALUE IN HEALTH, 2016, 19 (06) : 734 - 740
  • [6] Carcinogenic assessment of cobalt-containing alloys in medical devices or cobalt in occupational settings: A systematic review and meta-analysis of overall cancer risk from published epidemiologic studies
    Zhang, Shumin
    Holy, Chantal E.
    Eichenbaum, Gary
    Perkins, Laura E.
    Hasgall, Philippe
    Katz, Laurence B.
    Brown, Jason R.
    Orlandini, Luca
    Fessel, Gion
    Nasseri-Aghbosh, Behrooz
    Egnot, Natalie S.
    Zhou, Meijia
    Beech, Richard
    Marcello, Stephen R.
    Coplan, Paul M.
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2021, 125
  • [7] Examining the National Regulatory Environment of Medical Devices: Major Issues in the Risk-Benefit Assessment of High-Risk Devices
    Mathieu, Ghislaine
    Williams-Jones, Bryn
    [J]. MCGILL JOURNAL OF LAW AND HEALTH, 2015, 9 (01): : 17 - 68
  • [8] An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations
    Tarricone, Rosanna
    Banks, Helen
    Ciani, Oriana
    Brouwer, Werner
    Drummond, Michael F.
    Leidl, Reiner
    Martelli, Nicolas
    Sampietro-Colom, Laura
    Taylor, Rod S.
    [J]. EXPERT REVIEW OF MEDICAL DEVICES, 2023, 20 (04) : 259 - 271
  • [9] Guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or have endocrine-disrupting (ED) properties
    De Jong, W. H.
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2020, 111